Aspirin resistance: Current concepts

Reviews in Cardiovascular Medicine

Volumn 5, Issue 3, 2004, Pages 156-163

  Mason, Peter J ^a   Freedman, Jane E ^a   Jacobs, Alice K ^a  

^a BOSTON UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Antiplatelet therapy; Aspirin resistance; Coronary artery disease

Indexed keywords

ACETYLSALICYLIC ACID; ADENOSINE DIPHOSPHATE; ANTITHROMBOCYTIC AGENT; CLOPIDOGREL; CREATINE KINASE MB; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; DIPYRIDAMOLE; ENOXAPARIN; FIBRINOGEN; HEPARIN; ISOPROSTANE DERIVATIVE; LOW DENSITY LIPOPROTEIN; NONSTEROID ANTIINFLAMMATORY AGENT; PROSTAGLANDIN SYNTHASE; STREPTOKINASE; THROMBIN; THROMBOCYTE ACTIVATING FACTOR; THROMBOXANE A2; THROMBOXANE B2; TISSUE PLASMINOGEN ACTIVATOR; VITAMIN K GROUP;

ATHEROSCLEROSIS; AUTOANALYZER; BLEEDING TIME; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CIGARETTE SMOKING; CLINICAL TRIAL; CORONARY ARTERY DISEASE; DIAGNOSTIC TEST; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG RESPONSE; DRUG SAFETY; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HUMAN; LABORATORY TEST; MOLECULAR BIOLOGY; POPULATION RESEARCH; PREVALENCE; PRIMARY PREVENTION; RECURRENT DISEASE; REVIEW; RISK ASSESSMENT; SECONDARY PREVENTION; SIDE EFFECT; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION; THROMBOCYTE FUNCTION; THROMBOSIS; TREATMENT FAILURE;

ASPIRIN; CARDIOVASCULAR DISEASES; DRUG RESISTANCE; FIBRINOLYTIC AGENTS; HUMANS; PLATELET ACTIVATION; PLATELET ADHESIVENESS; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS;

EID: 4544335691     PISSN: 15306550     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (49)

1. Steering Committee of the Physicians' Health Study Research Group. Float Report on the aspirin component of the ongoing Physicians' Health Study. N Engl J Med. 1989;321:129-135.
2. Antiplatelet Trialists' Collaboration. Collaborative overview of randomized trials of antiplatelet therapy. I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ. 1994;308:81-106.
3. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ. 2002;324:71-86.
4. Yusuf S, Zhao F, Mehta SR, et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST segment elevation. N Engl J Med. 2001; 345:494-502.
5. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. Lancet. 1988;13:349-360.
6. Grotemeyer KH, Scharafinski HW, Husstedt IW. Two-year follow-up of aspirin responder and aspirin non responder. A pilot-study including 180 post-stroke patients. Thromb Res. 1993;71:397-403.
7. Buchanan MR, Brister SJ. Individual variation in the effects of ASA on platelet function: implications for the use of ASA clinically. Can J Cardiol. 1995;11:221-227.
8. Pappas JM, Wistengard JC, Bull BS. Population variability in the effect of aspirin on platelet function. Implications for clinical trials and therapy. Arch Pathol Lab Med. 1994;118:801-804.
9. Gum PA, Kottke-Marchant K, Poggio ED, et al. Profile and prevalence of aspirin resistance in patients with cardiovascular disease. Am J Cardiol. 2001;88:230-235.
10. Eikelboom JW, Hirsh J, Weitz JI, et al. Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events. Circulation. 2002;105:1650-1655.
11. Gum PA, Kottke-Marchant K, Welsh PA, et al. A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease. J Am Coll Cardiol. 2003;41:961-965.
12. Chen W-H, Lee P-Y, Ng W, et al. Aspirin resistance is associated with a high incidence of myonecrosis after non-urgent percutaneous coronary intervention despite clopidogrel pretreatment. J Am Coll Cordiol. 2004;43:1122-1126.
13. CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischemic events (CAPRIE). Lancet. 1996;348:1329-1339.
14. Mehta SR, Yusuf S, Peters RJG, et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percotaneous coronary intervention: the PCI-CURE study. Lancet 2001;358:527-533.
15. Steinhubl SK, Berger PB, Mann III JT, et al for the CREDO Investigators. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: A randomized controlled trial. JAMA. 2002;288:2411-2420.
16. Jneid H, Bhatt DL, Corti R, et al. Aspirin and clopidogrel in acute coronary syndromes: Therapeutic insights from the CURE study. Arch Intern Med. 2003:163;1145-1153.
17. Cipollone F, Rocca B, Patrono C. Cyclooxygenase-2 expression and inhibition in atherothrombosis. Arterioscler Thromb Vasc Biol. 2004;24:246-255.
18. Rocca B Secchiero P, Ciabattoni G, et al. Cyclooxygenase-2 expression is induced during human megakaryopoiesis and characterizes newly formed platelets. Proc Natl Acad Sci. 2002;99:7634-7639.
19. Patrono C, Coller B, Dalen JE, et al. Platelet-active drugs: the relationships among dose, effectiveness, and side effects. Chest. 2001; 119:39S-63S.
20. Patriginani P, Filabozzi P, Patrono C. Selective cumulative inhibition of platelet thromboxane production by low-dose aspirin in healthy subjects. J Clin Invest. 1982;69:1366-1372.
21. Weksler BB, Pett SB, Alonso D, et al. Differential inhibition by aspirin of vascular and platelet prostaglandin synthesis in atherosclerotic patients. N Engl J Med. 1983; 308(14):800-805.
22. Quinn MJ, Aronow HD, Califf RM, et al. Aspirin dose and six-month outcome after an acute coronary syndrome. J Am Coll Cardiol. 2004;43:972-978.
23. Awtry EH, Loscalzo J. Aspirin. Circulation. 2000;101:1206-1218.
24. Nicholson NS, Panzer-Knodle SG, Haas NF, et al. Assessment of platelet function assays. Am Heart J. 1998;135:S170-178.
25. Homoncik M, Jilma B, Hergovich N, et al. Monitoring of aspirin (ASA) pharmacodynamics with the platelet function analyzer PFA-100. Thromb Haemost. 2000:82;316-321.
26. Malinin AI, Atar D, Callahan KP, et al. Effect of a single dose aspirin on platelets in humans with multiple risk factors for coronary artery disease: Eur J Pharmacol. 2003;462:139-143.
27. Wang JC, Aucoin-Barry D, Manuelian D, et al. Incidence of aspirin nonresponsiveness using the Ultegra Rapid Platelet Function Assay-ASA. Amer J Cardiol. 2003;92:1492-1494.
28. Freedman JE. CD40-CD40L and platelet function: beyond hemostasis. Circ Res. 2003; 92:944-946.
29. Mehta J, Mehta P, Burger C, et al. Platelet aggregation studies in ceronary artery disease. Part 4. Effect of aspirin. Atherosclerosis. 1978; 31(2):169-175.
30. Helgason CM, Bolin KM, Hoff JA, et al. Development of aspirin resistance in persons with previous ischemic stroke. Stroke. 1994; 25:2331-2336.
31. Macchi L, Christiaens L, Brabant S, et al. Resistance to aspirin in vitro is associated with increased platelet sensitivity to adenosine diphosphate. Thromb Res. 2002;107:45-49.
32. Andersen K, Hurlen M, Arnesen H, et al. Aspirin non-responsiveness as measured by PFA-100 in patients with coronary artery disease. Thromb Res. 2002;108:37-42.
33. Grundmann K, Jaschonek K, Kleine B, et al. Aspirin non-responder status in patients with recurrent cerebral ischemic attacks. J Neurol. 2003;250:63-66.
34. Grotemeyer KH. Effects of acetylsalicylic acid in stroke patients. Evidence of nonresponders in a subpopulation of treated patients. Thromb Res. 1991;63(6):587-593.
35. Mueller MR, Salat A, Stangl P, et al. Variable platelet response to low-dose ASA and the risk of limb deterioration in patients submitted to peripheral arterial angioplasty. Thromb Heamost. 1997;78:1003-1007.
36. Alexander JH, Harrington RA, Tuttle RH, et al. Prior aspirin use predicts worse outcomes in patients with non-ST-elevation acute coronary syndromes. PURSUIT Investigators. Platelet IIb/IIIa in Unstable angina: Receptor Suppression Using Integrilin Therapy. Am J Cardiol. 1999;83(8):1147-1151.
37. Antman EM, Cohen M, Bernink PJ, et al. The TIMI risk score for unstable angina/non-ST elevation MI: a method for prognostication and therapeutic decision making. JAMA. 2000; 284:835-842.
38. Hung J, Lam JYT, Lacoste L, et al. Cigarette smoking acutely increases platelet thrombus formation in patients with coronary artery disease taking aspirin. Circulation. 1995; 92:2432-2436.
39. Catella-Lawson F, Reilly MP, Kapoor SC, et al. Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. N Engl J Med. 2001;345:1809-1817.
40. Kurth T, Glynn RJ, Walker AM, et al. Inhibition of clinical benefits of aspirin on first myocardiat infarction by nonsteroidal anti-inflammatory drugs. Circulation. 2003; 108:1191-1195.
41. Pulcinelli FM, Pignatelli P, Celestini A, et al. Inhibition of platelet aggregation by aspirin progressively decreases in long-term treated patients. J Am Coll Cardiol. 2004;43:979-984.
42. Hurlen M, Seljeflot I, Arnesen H. Increased platelet aggregability during exercise in patients with previous myocardial infarction. Lack of inhibition by aspirin. Thromb Res. 2000;99(5):487-494.
43. Larsson PT, Wallen NH, Hjemdahl P. Norepinephrine-induced human platelet activation in vivo is only partly counteracted by aspirin. Circulation. 1994;89(5):1951-1957.
44. Kawasaki T, Ozeki Y, Igawa T, et al. Increased platelet sensitivity to collagen in individuals resistant to low-dose aspirin. Stroke. 2000; 31:591-595.
45. Valles J, Santos MT, Aznar J, et al. Erythrocyte promotion of platelet reactivity decreases the effectiveness of aspirin as an antithrombotic therapeutic modality: the effect of low-dose aspirin is less than optimal in patients with vascular disease due to prothrombotic effects of erythrocytes on platelet reactivity. Circulation. 1998;97:350-355.
46. Maclouf J, Folco G, Patrono C. Eicosanoids and iso-eicosanoids: constitutive, inducible and transcellular biosynthesis in vascular disease. Thromb Haemost. 1998;79:691-705.
47. Morrow JD, Hill KE, Burk RF, et al. A series of prostaglandin F2-like compounds are produced in vivo in humans by a non-cyclooxygenase, free radical-catalyzed mechanism. Proc Natl Acad Sci USA. 1990;87:9383-9387.
48. Undas A, Brummel K, Musial J, et al. Pl(A2) polymorphism of beta(3) integrins is associated with enhanced thrombin generation and impaired antithrombotic action of aspirin at the site of microvascular injury. Circulation. 2001;104:2666-2672.
49. Michelson AD, Furman MI, Goldschmidt-Clermont P, et al. Platelet GP IIIa Pl(A) polymorphisms display different sensitivities to agonisis. Circulation. 2000;101:1013-1O18.